Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
So welcome to the seminar, Jan-Eric Österlund, Petter Segelman Lindqvist, and Roger Tell. Merton. Andre. Just a tiny bit. Over a year ago, AACR members. They can see some finer points near the Oberon to Barkerend. Oh, Oberon. To who long had their target seen like a welcome from Isofol sedan. Oh, hello Sturluson, her scarf waved before eventually the scene changed to new developments in cancer therapy. Regarding our development, we are focusing on what we can offer in the sector with Isofol. We are specialists in colorectal cancer and related cancers affecting the gastrointestinal tract. Can Shiragi stop us tomorrow? So the genome and treatment cytostatic or the Staatlichen we discuss colorectal cancer are FOLFOX or FOLFOX are they combat horrors, many or horror. Lastly on my wall, a report by Roger Tell may seem to imply that we are blocking the building of new cancer cells or tumor crimpers, which is best for their situation when the stable reaction occurs. I enjoyed her descent from amateur on the Frogger when they entered a new sector. Some can doubt the impact cancer accelerates or terminates. Bengt Gustafsson som sitter här han in såg Tedi at Oman. Using Methylenetetrahydrofolate directly in the body instead of Leukovorin can improve the effect, and he started more than 32 times. Simmons created a bullet point to highlight Methylenetetrahydrofolate. Oh, dear, oh, dear, oh dear. Sumire. Arfolitixorin. Sumire. Balsam for Isofol. So it's a false uplift there at best to set it as Arfolitixorin. Milk milk combination. My Andhra league medal made from MTHF combines with oxaliplatin. We had not heard from Dr. Arlene Herrera and her team made a unique analysis of other drugs or evaluated potential first-line or warning signs. We must also ensure these are in clinical study. We saw that, ultimately, with Leukovorin, there was a higher efficacy score with Arfolitixorin regarded as the best option. Or who can we visit in the clinical study at the bitter end, Leukovorin. Therefore at the AGENT study presented at AACR, Marietta attended. Then we observed that Arfolitixorin performed better than Leukovorin in the study, showing improvement in specific conditions often seen as challenging, according to the oxo and antol study analysis. So help us determine if Arfolitixorin in another dosing regimen can provide a better effect. Oh come on, Arfolitixorin can also be set in another combination, and a smaller dose was reported in the recent press release. Elle NE veut at We have Much Love and resulted from all of our analysis by Peter Roger, and André Breton in the summary. We used to have the AGENT study mentioned in a letter to Professor Hjalmarsson Visser regarding the FOLFOX protocol. In the study, we recorded that all patients had followed the protocol exactly. The treatment and care had been followed. The protocol resulted in Arfolitixorin. Indeed. Betulae, Petra, and Leukovorin. Amen. From Upminster and with us is Ciaran Harvey. The AGENT study analysis indicated that Arfolitixorin may lead to better results when used in combination with other treatments in the ongoing study. These are intended for summer walks normally again at the AACR, reminding about Arfolitixorin for enhancing treatment efficacy. There is some incentive to eradicate a cancer cell, a vector entity, or identify the first individual to become available online. Helena Tallinn, as mentioned in the context of the study, had a significant contribution to its outcome. Model study findings demonstrate significant effects with Arfolitixorin at higher doses. Better start your. Organoids that have been developed or tested at laboratories, such as Chittagong and Gothenburg. Here are some studies that are focused on going forward. So her main laboratory is at Amazon. Peter Rabbit. Mirror. About this. Men. Therefore, we are careful to maintain transparency and accuracy in all broadcasted content. Analysis. AGENT-studien. So we had a flag. Does it become a new alphabet? A dozen men, even then. A dozen men behind a better result. Struck the coast. That we are little Siena. Poor grown men knew that we were stuck. We'll make mire. And what we waste is our boredom. Human skull behind the patient or human skull. Through designing and conducting clinical studies, we gained substantial insights. Is there any consideration regarding the air quality during the summer for the financing of her project by Brian Harman? We fought Minsk at the risk of Minsk. We are at Santiniketan for one year. So after that, under Warren, our first American horse breeder, or secondly, I walked out. So we knew we had it in the money. We shall ignore Heller, Warcraft, the designer, and the clinical study. New tattoos or soccer in soccer or Roger Tell's operetta about this but media. So abroad at the ENA over to Petter Segelman Lindqvist for ASCO on the platform or conference. Good.
Evening, Eric. Three of us are here and also her roommate online. They educated Halvorsen, Isofol's sister, in the Army of the Orient. Mike sends me data and information from near Tybeke. Interesting. We come from three places with Johnny Eriksson. So we go here to the Evidence Platform for the province. We come to a mere Italian dinner study till I come back from commercial aspects and the commercial potential. Then I project from oxo. Oh my lord, Johnny Erik Demaine. Welcome on board here at OXO via the platform available online. A little written disclaimer, most of which are forward-looking statements. Attend the business affairs at Nicea. Please review the presentation. Let's build a sketch of a minesweeper. Warfare. Arfolitixorin plays an important role and is the foundation for the company, with three components from the medical field and other potential products that may help in treatment or the 3D realm. Commercial aspects. The significant potential and we strive to achieve it. To promote the Slutet Programmet, the culmination of the Medicinska Behovet program, for the Academy focuses on colorectal cancer treatment. The problem at hand is significant, with a database indicating 174,000 cases per year or 73 percent involving either local progression or metastasis. Tumor. Prognosis. Also, all medicines convert, so approximately 86% of patients are targeted in some form from diagnosis. So open the door to the most extensive foundational treatment regimens; first treatment follows Principle II, senior DSM generic with 5-FU as the main component, as well as Leukovorin for synergy, which is commonly used, or Arfolitixorin for its potential in improving outcomes. Leucovorin. So the A direct. Metastasis or simply some anomalies in a patient. So can we come in here. And so can the. Patient. The important position of Arfolitixorin is to offer a better mechanism than Leukovorin, as the body requires Leukovorin to be converted into its active metabolite to see an effect. So. Converted or metabolized in the body. In Dota Underlords. The evidence platform clarifies some generic broad daylight insights. We are new at least at Isofol. Now we have a data underlords. We're focused on the force. We. Have so much data or so much evidence from the products we buy to study for Arfolitixorin or leverage the outlook for progress. Is larger than normal for a product at. The storage of all components of the German Air Force in the AGENT study. We are at the circuit as well. Additionally, we observed in the AGENT study that there was an improved effect. Leucovorin then we saw the effect of liquidity on doors and windows. I then studied data from Jan-Eric Österlund and conducted a post hoc analysis per protocol, concluding that the effects were better with Arfolitixorin compared to Leukovorin. Study some evidence in her in vitro preclinical study. So while there is some new data points, there is still a case there. There are some new data points; however, the case remains. So then, the evidence platform was constructed by the same builder for three components. Then first perform some SAR analysis on Arfolitixorin to understand that effect. on product. Management. Class. Act number two. We are also set up to reduce the administrative burden. Set in effect, we are also triggered. Jetman can enhance the Arfolitixorin profile with a synergistic mechanism. ASCO trigger in Italy or one of them when? We looked at active products and then observed the effect. AGENT study data show per protocol analysis, and we observed a better effect with leucovorin under her annex protocol with the exact same build from her. Per protocol analysis and some masking, we. In the abstract, I was asked to address Congress about gastrointestinal cancer. Oh. Oh. January in San Francisco. Your men see her and swear to me that I can breathe. So we ran our patient population through a patient interview protocol. And then two main factors were observed: Arfolitixorin had a major effect on Leukovorin. We all included the regional. I understand the concern. Japan. So, Japan. Stick that in there. Oh. In Japan, over half of Japanese patients. Somerset. For some reason. Then we try to find some DNA analysis. And we mentioned that normally not in Japan, just to warn us about Arfolitixorin, I will fill in some fixing form for those registered. Regarding patients. I open doors for patients. I open the Arfolitixorin for potential 5-FU, considering the effect of Leukovorin on the production method. So can Arfolitixorin get some data or analysis until the patient is registered? I board Arfolitixorin for some fixed Leukovorin. Amen. Although there is no effect, even in Japan. To her advisor, the focus is on assessing the potential of any products in her store. To deal with the evidence platform, doses are administered per day to achieve a better effect or to. Execute just the AGENT study. AGENT study production's full potential is achieved through more than just mere administration. That might be an unusual assumption. And an error. 5-FU's full mechanism of action involves the inhibition of thymidylate synthase. My poor, poor girlfriend. So where? Does that come? From? Food metabolism. Intracellular FdUMP binds until Moreland meets TS or TS. Many will focus on the core aspects with dedication to improving their intricate systems. Melan FdUMP interacts with stable MTHF and Arfolitixorin, an active metabolite of Leukovorin that forms concentration complexes. This complex may bind quickly, forming an effective set. Out of two major thymidylate synthase inhibitors. So at the concentration of both FdUMP and MTHF, a synergistic mechanism can be activated, as evidenced in the AGENT study by Molly van der Haugerud, aiming for optimal dosing and logistics. Poor man. The AGENT study indicated that administering a low dose of Arfolitixorin is beneficial for patients. So, with the dose of Leukovorin being administered, it became challenging to manage Arfolitixorin 5 minutes after 5-FU due to the complex interaction. Since MTHF and Leukovorin are lacking in the complex, builders and Arfolitixorin fans face an open risk if they complete the version. Molin said complex building had started with MTHF to form a stable complex set of anti-tumor effects to inhibit cancer cells. Therefore, the comet from the store was exposed to a low dose of sunlight. Gordon also felt that there might be an optimal synergistic version available. New designs are needed for further study and alteration. The constitution with complex material desktop or comet publication system. He acquired many new tools and so forth. And then on the Evidensplattform, differing doses can lead to better effects. And then we had the model study in Bochum. I think any target system. Sturdier Evidensplattform tumor. Homogeneous study. Some of her. Scholarly publications by Serena van der Meer. Proven by Der Meer. Van der Meer Arfolitixorin improves upon Leukovorin as an effect marker, deoxyuridine, and serves as a surrogate marker for use as a benchmark for Andrea Monaco's work. Uh, the difference in the dose-response for Holland, they will say again, highlights the effect near Dawson. Also, there is signal learning with Leukovorin. Dawson Arfolitixorin and Harvey examined tumor studies on presenters for two months with late-breaking abstracts, and Congress wanted to arrange a meeting for the discussion of Arfolitixorin strategies. MTHF. 5-FU. hauger. Dawson and Hauger. Manga or effect or activity. Jackson at the AACR and Rupert George Dawson. The abstract for Arfolitixorin activity shows a positive concentration effect. The model examines the study of liver metastases. So we've already seen this at an early stage. So let's proceed to the study concerning the humanitarian aspect of the award, which was publicized at Media Arts. The student group investigated Arfolitixorin and its dose-response study for potential uses in Holland. It was about the core and the evidence platform. Uh, just precise. Oda Mae. Secrets. Secrets. Profile. Clinical study. Arfolitixorin has been administered up to 500mg, or 60mg in the AGENT study, with up to 240mg used in patients with colorectal cancer. Also for treatment, simultaneously, consider an infusion of Arfolitixorin, especially for patients with a risk of cardiotoxicity under certain conditions. There can be no injections. So they are building a foundation for the evidence platform, ensuring there is robust evidence for the study. In the good results from the three studies and the evidence platform, we can indeed shape the design of the study. Not until the outcome is evident. Estudiando. La historia de cote Roger Tell. As in the case of Italy. Arfolitixorin can reduce the Hauger effect. AGENT study. The coincidence. Oh, dear. Oh, dear. Optimal synergistic leucovorin. Melon. Vermifuge. Arfolitixorin protocol. The optimal profile and means of precision. Precisely so. Namah. On January forum. And media. So. Thank you. Clever. Oh, CNN orc. Welcome to Roger Tell. Where the Chief Medical Officer presented detailed findings from her study. So she's a little stunned. Petter.
Thank you for your contribution. Thank you for your comment. Lacuna Beretta alla Italia. Deal of the zombie. Come on, son. We are partnering with Beretta. So awesome. Okay, so at some point we heard. So how were you involved in the effort to gather feedback. So first of all, exactly where we were at for her to understand. The very long process. So it doesn't fulfill us. Leucovorin at the fastest. Jennifer 1043 study with well-documented mesh data. We. 100% pure. We use FOLFOX. We can. Visa. Visa. Visa. We performed better with Leukovorin. Maybe there are some secrets. The daughter will get a much different idea. We knew we had some places we liked to apply. Publishing house of Franz Steiner, Publishing house of the man, the man the son. Publishing for optimal results, Osnabrück. Visa for the same thing, Mordellina, in your vault at Punita. Visa. An artist in Haugar's effect dom model we invent, also come, we need AACR now. Let me. Go. In your study, there is an argument for tomorrow's strategies to be discussed. Discussion. We had people coming from all over. The city was the focus of the study. We called her Dom Primeira Malan, who took the first set. Delon de dos som de Boer. Mollett men as seen. Some of the wittiest names. Dawson ochok. So better refine the prototype. Tom, her precise senior, went first. For her, it does not mean it does, nor was it regulated or inclusive. FTA, I will see. Atman. You're aware. Exactly. Saying. Have you? Have you ever conducted a study? And then the one that is IL vostro. As it is crucial to perform an effective evaluation. Then we also presented this at ASCO. I will go to my flat and study. As such, we conducted the pivotal study and registered the foundational studies to help. So we have something new at the Key Opinion Leaders Summit. Senior lecturer in the world as we come. The scholar's reputation has spread widely across regions. The sun. We also come. We sat at the so-called treatment. Naive patients are those not yet receiving treatment for CIN metastasis and colorectal cancer. We've overseen the treatment, focusing on the patient group, for us based on an analysis of the AGENT study. Bevacizumab. Avastin or a combination of these drugs is used in conjunction with the AGENT study treatment as a strategy for patients in the trial, aiming to optimize their therapeutic outcomes. Dawson and. For a treatment and administering it 12 times. Optimal basis established for analysis of the AGENT study. Knox completed their analysis and. Design an and analyze data effectively. Deal to come up to 400 mg per kg. Excuse me, sir. We conduct some infusions. We require patients to come in after the maximum tolerated dose is introduced in the first four sessions or so, and never enroll under 30 patients. So, a total of 60 patients were at her facility for the study at Craiova. Per. Ulica Faustina. Focus. My. The main focus is to deal with tolerability and pharmacokinetics. So. It's also become a theater effect versus a broader response. So the first projections for that. Effects come from the Fukushima disaster response. And so we come to a total of 11th circuit altimeter. Okay. Van der. So. Von für als biomarker body blood men. Okay. So, some material for analysis. Eau de vie de Elon. Musk como por la guerra framat och dom Harvey Typekit sa Walt Bird Aprovado center for studies. In her latest analysis featured in Ondskan. And the first hereditary work in the BFM, the task Mindy Mindy Nye Roopa for the Internet of Medicine. Board for studying medicine. Collaboration with Germany and. We are intrigued. That made her Mindy a vote. For Eau de Vie inventor, her understanding of data is crucial for. Uh, at the docks for the next hour. The rest of the deal was at. Studio time at Winter Park for Froggy. Froggy? So Scatman snapped at some of the issues. Et cetera. So come on in here, Dr. Herr, Mr. Herr. Study center as Tyler et al. center. Dom för. Then per se. So here we were. We hope to reach Shenandoah and Atman. Star. Recruit. As a senior member. Dylan. Topline data can be achieved within six months after the initial days of study commencement, ensuring that. We do not currently have Professor Sebastian Stintzing as the study leader. Students can complete and coordinate the provision for Austrian charity for oncology hematology. Kliniken och professor Stintzing har namnet och värdet med AGENT-studien och för koordinerade prövningar i Tyskland. Han har lång historia med oss. Yet Claudia Han Punnett will study thematically and lead the progress, she is enthusiastic and has a little booklet of messages from Germany.
So, dear ladies and gentlemen, it's a pleasure for me to talk to you about Arfolitixorin and the new studies. We want to start as soon as possible. First of all, to introduce myself. My name is Sebastian Stintzing. I'm heading the Department of Hematology, Oncology, and Cancer Immunology at Charité in Berlin. And my working group is really focusing on clinical research of GI cancers. And my special focus, of course, is to optimize treatment for our patients in metastatic colorectal cancer. We will look into the current standard of care options for treating colorectal cancer applicable to 95% of all patients, except for those with MSI-high tumors. So, 95% are today treated with a 5-FU Leukovorin-based chemotherapy, either with a combination of FOLFOX, which is 5-FU Leukovorin plus oxaliplatin, or FOLFIRI, which is 5-FU Leukovorin plus irinotecan. Even when we look into the larger developments today, like precision oncology for specific small groups of patients, such as the BRAF V600E mutant patients, which accounts for around 8 to 10% of the metastatic setting. We have seen the first studies where a chemo-free therapy was given, but nowadays those are also combined with standard of care chemotherapy. 5-FU based chemotherapy. And the first data we have witnessed earlier this year just show amazing results. So the combination of precision oncology plus chemotherapy, 5-FU based chemotherapy, will still be the standard of care for the wide majority of our patients. Talking about some 5-FU and colorectal cancer, I think it's important that, you know, 5-FU and folinic acid is not only used in the metastatic setting, which we will see around about 1.9 million patients per year worldwide, but also in the adjuvant setting. 5-FU based chemotherapy has stood the test of time and is a standard of care treatment. When we talk about colorectal cancer, colorectal cancer or GI malignancies account for around 25% of all malignancies worldwide, and colorectal cancer accounts for around 12.5% of all malignancies worldwide. So I think what we have seen is important. When we are able to improve the efficacy of 5-FU and Leukovorin, we will have the ability to significantly enhance the efficacy of these chemotherapeutic backbones for a vast majority of patients. And that's why we really are excited to participate in the new Isofol trial, aiming to improve the efficacy of 5-FU plus Leukovorin or 5-FU plus Arfolitixorin. So we are really excited to start this treatment. And the good news is it's not like a typical Phase One trial because we already have the data from the Phase Three Isofol trial, the AGENT trial, where several hundred patients were treated, and the lower dose Arfolitixorin showed the same efficacy or at least comparable efficacy to Leukovorin. And what we want to do now is really to increase dosage, because preclinical data has shown us that we will have better efficacy with a higher dosage. And also when we look into the toxicity data, we do not expect unexpected toxicity so far, because higher doses were already given to a small number of patients before. And now we will really see if we can use these higher doses to, um, enhance the efficacy of these drugs. And of course, colorectal cancer is not the only, um, GI cancer where 5-FU plus Leukovorin is used today. It's also used in gastric cancer, which is a very important cancer for the Asian population. It's more important in the Asian population than in the European population. But even there, 5-FU-based chemotherapies are the basis of most treatment options, not only in first-line, but also in second and third-line treatment. And also when we look into lung cancer, we have pemetrexed, which is also a Thymidylate Synthase inhibitor. So even in other tumor entities outside the GI focus like, um, lung cancer or, um, like breast cancer, uh, TS inhibitors are used today. So there's great potential for the substance Arfolitixorin if we are able to show higher efficacy than the standard of care. 5-FU plus Leukovorin. So overall, I think Isofol has done a great job so far. We have chosen a very responsive and very active crew, and I'm happy to start the new Isofol trial as soon as possible, probably early next year, with the first patient to be treated with higher doses of Arfolitixorin to show hopefully higher efficacy. Thank you so much for listening to me.
Your talk. Sebastian Stintzing for ASCO and their Isofol as Professor Stintzing for the. Some charity here, the best place for Sebastian Stintzing is invalid. And obviously I felt that the story was also a stark signal to hand over to my house. So, uh, more major charity as some center. Services are set up there for developing the evidence platform regarding medical aspects, focusing particularly on sports health and new proteolytic mechanisms. E Ward E dog sells for 67 million kronor over Hela. Jordan. Oh oh 34, so Denmark has Wexler and the big ones. So we are going to see our combination and FMF bosun is handling it first for the majority of patients in her building. About the illustrated mutation, patients have more. In 95% of cases, the treatment in The Hague uses Arfolitixorin as an alternative to oxaliplatin. Now we come to a small group, or 10%, of patients. The group, or most of them. There are four types of chemotherapy. Things like Nora and Andrea and together or in principle as Leucovorin as a component or Leucovorin as Arfolitixorin for openings, can, can, etc. So, consider Arfolitixorin as the main component. So you're in a situation where we can launch a product with a new study, allowing a little more time to focus our analysis. The future for Lance Enders in the middle of Montana. We redo coming from till at den Bosnia come, war rendered the fields medal we pipeline. So let me, let me see her attractiveness. Oh, we can, we can behoove the Finns. Oh, frame your product, the next product. Na. Na na na na. Chemotherapy or therapy in the domain. The thing that chemotherapy killed. Harvey Froggatt, a clinical expert and opinion leader in the USA, provides pure qualitative insights. Becoming an author. See also. Further, Back Bay Life Sciences is an American consulting firm that has provided insights into the biotechnology sector. An operations leader. So it is inconceivable to think that 5-FU backbone will not be the mainstay. Regarding the non-answer, it's clear that 5-FU is the most effective drug in treating this disease. I don't think it will ever go away. Ever. When you say 5-FU will remain the pyrimidine of choice in multi-agent chemo regimens in first-line, so then consensus also agreed with her ex-partner, USADA, and Roberto de Venecia. Mr. OC Arfolitixorin discussion was focused on its development and integration into treatment plans. I realized in just the first line, and regarding the German Arfolitixorin, we had to incorporate some adjustments and considerations for it. Inclusive of Isofol until we had a blockbuster potential product, and then a blockbuster envisioning for a million dollars or million million kronor per liter. Profits, oh oh. Truly positive analysis. Oh, come on, say a worthy craft. Adam, estimate some Isofol lemonade for the man who discovered its potential, and also for an upstart, or for Clara who ran from her Nora. Nora. Groove. And then we can deduce that the model of Victoria is a novel component for the American population. It is noted as an important component for treating metastatic colorectal cancer, particularly in targeted areas. For fem behandling does come from an addressable population of 605,000 individuals per year. For Arfolitixorin or its components. The first preset wicked price can be attributed to investors like Evan who had invested in research at Back Bay Life Science Advisors at a significant price premium for the Arfolitixorin factor. Mr. Miller truly saw the fort from my clinical opinions and had a meaningful effect. The effect over leucovorin is observed in Arfolitixorin. VR model and penetration for 70% as Leukovorin 70%. So a little conservative. So we organized multiple simulations or trials, conducted assessments, and continued treatment planning for the patients every hour or so. 2 million kronor per year. Year. So they can come. From Hawaii, Japan, or Canada to manage their Isofol or commercial partners. Natural Europe for borders. Oxo is interesting, or Arfolitixorin can be. Can't hear a word? The same can apply to metastasis. Colorectal cancer in colorectal cancer. And then we heard Professor Stein discuss an adjuvant or neoadjuvant treatment for some somatic cells, which they may suggest in combination with surgery. Or they can say application for colorectal cancer. And the formula of solid tumors have been thoroughly studied. Although pancreatic cancer at Saint Sebastian's and lung cancer appear in different forms as skin cancer does. We will illustrate the potential for colorectal cancer. For gastrointestinal cancer. So Mahashakti also has a collaboration with Isofol. There are clearly significant potentials for Arfolitixorin to provide better prognosis for patients. Or we are set on potential, and then the strategy and our strategic approach. So, at the same time, Isofol could potentially face challenges with their product. Her potential at work can come in to offer revolutionary treatments for colorectal cancer, improving the quality of life for all of us. Very aware of the. Media might open up for me. Welcome. Cup for CNN.
Your talk, Peter, or Roger's presentation. New presentation for Irala at Roger Ward Neville. From your experience, through your insights, Matsuda. Do you have one microphone or can we say if they come from.
The Matsu La Palma? We have not heard from. The First World War, de facto, was a period when there were many changes. Can the 30%? Lot. More than. I remember. I also believe Leukovorin can still be replaced by Arfolitixorin in this ASCO presentation. Conclusion, just as good as Arfolitixorin, with them in the house. Maybe not. The old domain mannequin has been taken in the form of Leukovorin until. Arfolitixorin is a crucial element, demanding focused attention. In addition, some patients received Leukovorin. They must come from far away from the north. Or can we isolate them? The patient group has shown some improvement. And we hired.
Roger.
I am Petter Segelman Lindqvist. Poor biomarker AGENT study or the war just after the war. Man had hitherto remained unchallenged in his views on these matters. Held an exhibition among other things on transport proteins. So some. We couldn't prepare the AGENT study. We didn't give Monsieur Arfolitixorin some guidance from and after analysis. Some order is necessary so that we can develop a comprehensive strategy, allowing us to include advancements like Adam's complete art beyond routine protein analysis. We're just going to eventually identify effects on non-primary treatment outcomes. So we have all the data, and it's also set to go to Boca for the Dothan. New data on Arfolitixorin and Leukovorin suggest a strong potential effect on patients. For the negotiations.
There.
Spiegel am. Microphone.
Yo yo. Yo ho ho ho yo ho ho. Ho! Ho ho. American. ASCO. Departments. Ho hos and stolen servicemen. Non-medicinal. Candy. Fattening. Honey. You know, risk analysis of data.
First of all, your team can contact me. FTA.
Roger Tell their most significant node for FTA Europe orbiter mirrors the European Manhattan EMR also at CERN at uh at cooperation. Merlin. Münchhausen runtime could face FM records but also the Japanese PDM, while they prefer to say that. The focus of the film's final scene is highlighted after the film's finale. Definition of v v v. V V Rupa. We need to come together after reviewing her study and then contact Stella. Relevant to Roger Tell's FTA, 200 MC on for the next stage, confirm and understand feedback from men, so we can do some population biomarker analysis. Can you group some data for a little better value if we order from the AGENT study, the team doesn't arrive at Boca, so we come up with a similar plan to consider using materials from the Blue Room set.
So we got the specific arrival of the new health minister; her first effect was her answer to vaccinating individuals at risk for the same type of cancer from the same area. Even in the effort to free her from somewhere in Victor Hugo's work, some are working for Isofol alongside her dog.
Celia Arfolitixorin.
Van der Isofol.
Their two partners and their soldier. Paladin. Poland, Canada, and the character Salacia. Development and commercial collaboration. Madam. In Japan. Oxo commercially produced the Paladin range as part of their commercial war planning. Thirty years after we left the Air Force, we are distancing ourselves from the air warfare period. Utveckling. Oxo. Japan. Air. So I can see an enthusiasm for isolation. I'm glad for that. Well, it got a collaboration between wars. Paladin. So good. Until then, her intensity was on my side. So, after a day at Boulogne-sur-Mer. Went on a commercial product for versioning.
Track for their VR in-flight event. So I, Rick Hansen, spoke to investors at the model, referring to the context from the Vietnam War and the TypeScript development. What happened there? Oh, there might be some model studies. Helena must retire today. Ian on microphone.
Then finds out from. Them. I don't like your oatmeal. Your dad is a Type Three monitor, man. FdUMP, as mentioned in a press release, linked with the article that I hope becomes a successful step like Lisa's many times for a well-run studio.
I overheard that you were at a studio or accepted for publication on the. IoT, internet, and the wider academic advisor are also very important areas to study Java and remote Java.
To Peter Ekman and an advanced practice nurse. I feel hopeless, as man can't go to her for help when feeling down. Rectum.
Can.
So then we also dove into her orderly manner and addressed her concerns. Dialogue with me now can also come home FDR, we can. Come up with a studio program to. Build and graft for her. Fawcett was planning a new informal study. There were poor men who came here often. Including the fastest man, one might say. Even there at Vassar. Alden generates so much value in constructive dialogue. My mind needs to dial up.
To overcome. That optimistic tone.
I will tell them about that optimistic data, some of whom we knew in FOLFOX. Then call me crazy and 46 minutes. Much can be simplified to ensure better outcomes.
You are.
Paying.
400 million light Drückt e Carson, Director Total Force, and be available at all top results. We attended Molestina at 10,000. Declared. That made a positive reaction. Som Vohra, from the studio, laughed under her breath. Oh, then the effect pertained to the situation for Andres and we had a similar biotech discussion to talk with you about future plans. You better wonder. Why don't we have an interaction. The example I'm telling Sam is about how long we plan to move forward. The Clippers say abandon or at least give examples and license and license together.
As an activity. The correct application and proper usage situation which sturdiness and clinical effectiveness concern. The situation protocol in the study is under development.
In honor of Urbieta, Schopenhauer. During the AGENT study, you noted that everything began at the same level with me and others, etc. So far in the Altai protocols, some Bulldogs or. Adam Sandler's film may not resonate with everyone, let's say, for fans of the Bulldogs. Some men. And at the end of the meeting, it's proven or not. Inadequate protocol. Handle it. Poor man. So, for the matter at hand. That's the strategy we have decided on. Not Vincent van der wallet of FOLFOX. Extremely hard to do that job. My fault. Let me get some air. Well, Studio Warner. Some can hear any air compressor study and then study. Some of the store. So, so, so, um. So. So we can expand our networks for. Free within the network. Uh, so. And also for Germany, um, men who provide support at the study team, someone at the cancer study. So, at the moment, we are better than high school.
Oh, yeah?
Well, we saw you up in Berlin. Per protocol analysis, we brought Adam Fury to the Sorbonne. It behooves school administrators. We. Need to study design. The board felt it behooved us to aim for precision with our substance and style. Nadine conducts herself exactly in the moment. Om. Damn her friends and. Say that their products are like rocket science and cleverly involve systems for Leukovorin in the development and delivery of products. Oh dear, oh dear. Under certain commercial DNA of reluctance.
To talk at all. So we went there for the study environment. We saw that we are not using Leukovorin. We are due for examining our current practices and those of potential future projects. We handle critical situations well, and we are well known within the organization for doing so in realistic circumstances. Not only the world's leading focus in Europe but also in all the Steadicam environments. We had little further inquiry. Rick Hari Jan drew attention with her interest in examples from the Bio Europe event year-round, representing Isofol, particularly under Orit Kan. Kan you tell us a bit more about this?
Representatives from your partner in Europe, as well as a congressional partner, attended the meeting. Da da da da. Partner for the Archimedes Project. Isofol. Da da da da da da. We had an interaction term. Ergonym Isofol project synergy. We were compelled to form a partnership. So we had established a relationship. Or start a relationship or add some freedom. Her name? My daughter. I talked to engineers. When your school gained attention from the CIA earlier that year, there was a fervent interest. That's for flair. Flair. Store. Store. My story about Isofol. Ha! So they were like. We cannot contact Fremtiden's main partner Arbetet, Isofol Medical AB, AG sin, Linda and Gründe. Boston.
New York, at the Ducks Marina at Clipper, we had Nora monitor the airport. We have an awesome marker. We can start for the night. Also, Stella provided some inspiration. Those new air ducts at Go Light are for the local Oak Harbor Light. Mingle some DNA from inlet welded together. All areas that have been reached via link 04 are deemed important thanks to the efforts accomplished at proto era after the meeting. Thank you.



















